Important Notice for Neumora Therapeutics, Inc. (NMRA) Shareholders
NEW YORK, March 26, 2025 – The Gross Law Firm, a leading securities litigation law firm, notifies investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (NMRA) in the United States District Court for the Southern District of New York. The complaint alleges that Neumora and certain of its officers and directors violated the Securities Exchange Act of 1934.
Background
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cannabinoid therapeutics. The company’s lead product candidate, NM-001, is a proprietary cannabinoid formulation in development for the treatment of chronic pain and inflammation. Neumora’s common stock is traded on the NASDAQ Capital Market under the symbol “NMRA.”
Allegations
The complaint alleges that Neumora and its officers and directors made false and misleading statements and failed to disclose material information regarding the company’s business, operations, and financial condition. Specifically, the complaint alleges that Neumora misrepresented the progress and prospects of its clinical trials for NM-001, including the safety and efficacy data, and failed to disclose material information regarding the company’s financial condition, including its cash position and revenue projections.
Impact on Shareholders
As a result of the above allegations, Neumora’s stock price has experienced significant declines, causing harm to investors. If you purchased Neumora securities between [Date], and [Date], and suffered losses, you may be entitled to join this action.
Impact on the World
The securities class action against Neumora Therapeutics could have far-reaching implications for the biotechnology industry, particularly for companies in the cannabinoid therapeutics space. Such lawsuits can lead to increased scrutiny of a company’s business practices and financial reporting, as well as potential damage to its reputation. Moreover, the outcome of the lawsuit could impact investor confidence in the industry as a whole.
Conclusion
If you own Neumora Therapeutics securities and believe that you have suffered losses as a result of the company’s alleged misrepresentations, you may be entitled to join this class action. The Gross Law Firm encourages investors to contact the firm as soon as possible to discuss their legal options. For more information, please contact The Gross Law Firm at (888) 297-1030 or [email protected]
This notice is not a solicitation to file a lawsuit and is not intended to provide legal advice. Please consult with an attorney regarding your specific situation.
- Neumora Therapeutics, Inc. (NMRA)
- Securities class action lawsuit
- Allegations of false and misleading statements and failure to disclose material information
- Impact on shareholders and the biotechnology industry
